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Abstract
Background: Puerarin, a phytoestrogen with a weak estrogenic effect, binds to estrogen receptors, thereby competing with
17b-estradiol (E2) and producing an anti-estrogenic effect. This study was to investigate whether puerarin could suppress
the invasion and vascularization of E2-stimulated endometriotic tissue.
Methodology/Principal Findings: The endometriotic stromal cells (ESCs) were successfully established and their invasive
ability under different treatments was assessed through a Transwell Assay. Simultaneously, matrix metallopeptidase 9
(MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) were detected by western blotting. Vascularization of
endometriotic tissues was observed by chicken chorioallantoic membrane (CAM) assay. The staining of MMP-9, intercellular
adhesion molecule 1 (ICAM-1), TIMP-1, and vascular endothelial growth factor (VEGF) in grafted endometriotic tissues was
examined using immunohistochemistry analysis. The purity of ESCs in isolated cells was .95%, as determined by the
fluoroimmunoassay of vimentin. E2 (10
28 mol/L) promoted the invasiveness of ESCs by increasing MMP-9 accumulation and
decreasing TIMP-1 accumulation. Interestingly, puerarin (10
29 mol/L) significantly reversed these effects (P,0.01). The CAM
assay indicated that puerarin (10
29 mol/L) also inhibited the angiopoiesis of endometriotic tissue stimulated by the E2
(10
28 mol/L) treatment (P,0.05). Accordingly, immunohistochemistry showed that the accumulation of MMP-9, ICAM-1,
and VEGF was reduced whereas that of TIMP-1 increased in the combination treatment group compared with the E2
treatment group.
Conclusions/Significance: This study demonstrated that puerarin could suppress the tissue invasion by ESCs and the
vascularization of ectopic endometrial tissues stimulated by E2, suggesting that puerarin may be a potential drug for the
treatment of endometriosis.
Citation: Wang D, Liu Y, Han J, Zai D, Ji M, et al. (2011) Puerarin Suppresses Invasion and Vascularization of Endometriosis Tissue Stimulated by 17b-Estradiol. PLoS
ONE 6(9): e25011. doi:10.1371/journal.pone.0025011
Editor: Jean-Marc A. Lobaccaro, Clermont Universite ´, France
Received June 28, 2011; Accepted August 22, 2011; Published September 15, 2011
Copyright:  2011 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant from the National Natural Science Foundation of China (Project No. 30672742, 30873353, 30930113) and 973
project (2010CB933902). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: chqyu81@gmail.com (CY); czl8003@hotmail.com (ZC)
. These authors contributed equally to this work.
Introduction
Endometriosis, a common, benign, estrogen-dependent disease
affecting 3%–10% of women of reproductive age, is defined as
the presence of endometrial glands and stroma outside of the
uterine cavity [1]. It is not a malignant disorder but it has
similarities to a developing tumor. For instance, endometriotic
cells can be both locally and distantly metastatic, that is they can
attach to, invade and damage other tissues [2,3]. The initial
phase of endometriosis is an invasive event that requires
extracellular matrix (ECM) breakdown. The key enzymes that
regulate the ECM are the matrix metalloproteinases (MMPs), and
peritoneal invasion by endometrial tissue is thought to be
dependent on MMPs and their corresponding tissue inhibitors
of metalloproteinases (TIMPs). MMPs play a pivotal role in the
cyclic changes of growth and tissue breakdown that occur in the
endometrium. MMPs are usually synthesized during the prolif-
erative phase and are stimulated by estrogen [4]. Several studies
have shown an increase in the accumulation of MMP-1, MMP-2,
MMP-3, MMP-7, and MMP-9 in endometriotic tissues. Alter-
ation of MMP-9 and MMP-2 is an important factor in the
development of endometriosis [2,3].
Vascularization of endometriotic implants is probably one of the
most important factors in the invasion of other tissues by
endometrial cells. Angiogenesis is controlled by a number of
inducers; of particular importance is the vascular endothelial
growth factor (VEGF) family, which is significant in processes
characterized by both physiological and pathological angiogenesis.
Accumulation of the VEGF gene in normal human endometrial
cells is acutely upregulated by E2 in vitro [5]. VEGF immuno-
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implants, particularly in hemorrhagic red implants [6].
Most of the current medical treatments for endometriosis aim to
downregulate estrogen activity. Historically, medical therapies
have included contraceptive steroids, progestogens, and agonists of
gonadotropin-releasing hormone (GnRH), as well as androgens
and non-steroidal anti-inflammatory agents [7]. These treatments
can only be used for a limited time because of unacceptable side
effects. In addition, high recurrence rates after medical treatments
are the most significant problem [8]. Therefore, exploring novel
therapeutic strategies is necessary for improving the clinical
management of patients with endometriosis.
Phytoestrogens exhibit estrogenic and anti-estrogenic activities
both in vitro and in vivo [9]. Puerarin, a phytoestrogen derived
from the Chinese medicinal herb Radix puerariae, has been
proven practical in the management of various cardiovascular
disorders, alcoholism, and neurological disease [10]. However,
whether puerarin could suppress invasion and vascularization of
endometriotic tissue is unknown.
Results
Establishment of the primary ectopic ESCs
Endometriotic stromal cells (ESCs) should be stained positive
with anti-vimentin-PE monoclonal antibody by fluoroimmunoas-
say. The negative cells could fibroblast cells, gland cells and
epithelial cells. The purity of ESCs in isolated cells was .95%
(Fig. 1).
Puerarin suppresses invasion of E2-stimulated ESCs
For the following experiments, 10
28 mol/L E2 and 10
29 mol/
L puerarin were selected because of their efficacy on ESCs in our
preliminary experiments. In Fig. 2A, 10
28 mol/L E2 showed a
stimulatory effect on ESCs invasion compared with the untreated
(vehicle) control cells, but the combination of E2 with puerarin
reduced this effect (P,0.01).
To characterize fully the anti-estrogenic effects of puerarin, we
analyzed the accumulation of MMP-9 and TIMP-1 under same
treatment. As shown in Fig. 2B, the accumulation of MMP-9 was
increased whereas the accumulation of TIMP-1 was decreased
after the E2 treatment compared with the untreated control. With
the combination of E2 and puerarin treatment, the effect was
significantly reversed.
Puerarin inhibits angiogenesis in CAM in vivo
To explore whether puerarin could inhibit vascularization of
endometriosis tissue stimulated by E2, we tested the in vivo effect
of puerarin on angiogenesis using a modified chick chorioallantoic
membrane assay. E2-treated CAMs showed well-developed zones
of neo-vascularization surrounding the sponge compared with
vehicle treated CAM, however, CAM neovascularization was
significantly suppressed by addition of puerarin (Fig. 3 A, B).
MMP-9, TIMP-1, ICAM-1, and VEGF immunostaining of
endometriotic xenograft in CAM models
MMP-9, TIMP-1, ICAM-1, and VEGF staining of the grafts
were shown in Figure 4. Treatment with E2 resulted in a stronger
MMP-9, ICAM-1, and VEGF staining and weaker TIMP-1
staining. Treatment with E2+puerarin decreased MMP-9, ICAM-
1, and VEGF staining and slightly increased TIMP-1 staining
compared with the E2 treatment, which suggests that puerarin
could suppress E2-stimulated angiogenesis of ectopic tissues by
regulating the related protein molecules.
Discussion
Isoflavones, as phytoestrogens, are of biological interest because
they exhibit estrogenic and anti-estrogenic activities both in vitro
and in vivo [11–14]. Puerarin, the main isoflavone glycoside
derived from the Chinese medicinal herb Radix puerariae, has
been proven practical in the management of various cardiovas-
cular disorders, alcoholism, and neurological disease [15,16].
However, its role in treating endometriosis, an estrogen-dependent
disorder, has not been well elucidated.
In this study, puerarin exhibits anti-estrogenic activity in a
model of endometriosis. The findings support our hypothesis that
Figure 1. Representative photomicrographs of the fluoroimmunoassay for vimentin in the isolated ESCs. The cells were stained with
DAPI (a, d), mouse IgG1 PE (b) and mouse-anti-human vimentin PE (e). The photographs (a and b; d and e) were merged on the right (c; f)
respectively.
doi:10.1371/journal.pone.0025011.g001
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angiogenesis of ectopic tissues.
The establishment of endometriosis has been attributed to the
attachment and invasion of retrograded endometrial fragments
outside the uterine cavity. The endometriotic tissue is composed
mainly of endometrial glands and stromal cells, as well as
extracellular matrix (ECM). Given that the retrograde ESCs are
responsible for the adherence and implantation of endometrium,
ESCs rather than endometrial epithelial cells were used to assess
the invasion of the retrograded endometrium [17].
MMPs can enable endometriotic tissue to digest into the ECM
and underlying connective tissue. TIMPs, which affect normal and
pathologic matrix remodeling, regulate the activity of MMPs.
Among the different proteolytic enzymes known to degrade ECM,
MMP-9 has been specifically reported to play a crucial role in the
regulation of the metastatic behavior of ESCs [18–21]. The
Figure 2. Effects of different treatments on the invasiveness of ESCs. Combination treatment of E2 with puerarin suppresses invasion (A)
significantly in ESCs compared with E2 treatment alone. Western blotting (B) was performed to determine the accumulation of MMP-9 and TIMP-1 in
ESCs treated with vehicle or E2 or E2 plus puerarin. **P,0.01, compared with the E2–treated cells. The results are expressed as mean 6 SD, n=6. The
final concentration of E2 or puerarin was 10
28 mol/L or 10
29 mol/L respectively.
doi:10.1371/journal.pone.0025011.g002
Figure 3. Puerarin inhibits angiogenesis in CAM in vivo. 10
28 mol/L E2 or combination with 10
29 mol/L puerarin or normal saline containing
0.1% DMSO (v/v) were loaded on gelatin sponges which were loaded on the chick chorioallantoic membranes of chick embryos respectively. After
72 h incubation, 10% v/v formaldehyde was added onto the surface of CAMs to fix the blood. The disc and surrounding CAMs were incised carefully
and photographed; representative photographs show the CAMs of 10
28 mol/L E2 or combination with 10
29 mol/L puerarin or normal saline
containing 0.1% DMSO (v/v) treatment groups (A). Number of visible blood vessel branch points are statistically shown (B). n=6, * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0025011.g003
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in endometriotic lesions. For the most part, MMPs are synthesized
duringtheproliferative phaseandarestimulated byestrogen.Inthis
study, we have demonstrated that ESC invasion through an
artificial basement membrane was increased when treated with E2
(10
28 mol/L).Theabilitytoinvadethebasementmembraneandto
migrate in response to the E2 stimulus was reduced after co-
treatment of ESCs with puerarin (10
29 mol/L). Moreover, western
blot showed thatthealterationofMMP-9and TIMP-1levelwasthe
possible mechanism for the anti-metastatic action of puerarin.
Endometriosis requires estrogen for its continued growth and, if
deprived of this hormone, it tends to regress. Estrogen plays a key
role in stimulating adhesion, invasion, and implantation of
menstrual endometrial fragments through its action on estrogen
receptors (ER). Reportedly, puerarin can treat endometriosis
partly by suppressing P450arom, a key enzyme for estrogen
biosynthesis [22,23]. Another study showed that phytoestrogens
act as aromatase inhibitors at low-concentrations [24].
We also focused on the suppression of endometriotic tissue
angiopoiesis by puerarin. Preparation of stromal cells and epithelial
glands cannot form endometriotic-like lesions in the CAM model
[25]. This occurs only when the tissue architecture of the
endometrium is preserved [26]. In the CAM model, the human
endometrium was observed as highly angiogenic and, therefore,
perfectly capable of stimulating blood vessel formation in the
surrounding tissues. The phenomenon was more pronounced when
treated with E2. This positive effect can be suppressed by co-
treatment with puerarin. Related proteins, including ICAM-1,
TIMP-1, MMP-9, and VEGF, are involved in the process.
Angiogenesis is a vital process in the development of
endometriotic implants, providing substantial background for
their further maintenance and growth. High levels of estrogen in
the microenvironment of endometriotic lesions stimulate specific
angiogenic growth factors such as VEGFs and ICAM-1. ICAM-1
has previously been linked to VEGF-dependent revascularization,
and they both play important roles in pathological process in
endometrial tissue [27,28]. Our data show 10
29 mol/L of
puerarin can significantly inhibit the effects of estrogen on
angiogenesis during lesion implantation.
The current standard medical treatments for endometriosis
include GnRH agonists, contraceptive steroids, progestogens, and
androgens [29–33], all of which aim to lower circulating E2
concentrations. Of these agents, GnRH agonists appear are the
mosteffective,buttheyareexpensiveandlong-termtreatmentisnot
possible because of the loss of bone mineral density. Progestogens
have the best clinical profile and a good cost-effectiveness balance;
however, most studies found that they are not as effective as GnRH
agonists. Oral contraceptives are only effective during treatment
and have a high relapse rate after therapy is completed. Markedly
high recurrence rates of up to 45% after current medical or surgical
therapy have been reported [34]. Therefore, exploring new
strategies for treating endometriosis is needed.
Clinically, the potential advantages for puerarin to treat
endometriosis are as follows; first, puerarin is able to bind to
ER-alpha and ER-beta [9], it can suppress P450arom activity as
aromatase inhibitors in endometriosis treatment, and it may be
applicable as an adjuvant to the current medical treatments.
Second, because puerarin can be used for long periods without
severe side effects, medical treatment with this agent is a good
option for avoiding disease relapse after the initial surgical and/or
medical therapy. Third, with weak estrogen agonists/antagonists
and some other enzymatic activities, puerarin is increasingly
advocated as a natural alternative to estrogen replacement therapy
and is available as dietary supplements.
In summary, we demonstrated that puerarin has anti-estrogenic
activity by interfering with the invasion of ESCs and angiogenesis of
ectopic tissues. These findings suggest that puerarin may be a new
and efficient product for the medical treatment of endometriosis.
Materials and Methods
Tissue collection and cell culture
ESCs were obtained from premenopausal patients who had
undergone salpingo-oophorectomy or evisceration for ovarian
Figure 4. MMP-9, TIMP-1, ICAM-1, and VEGF staining of the endometriotic xenografts in the CAM model treated with vehicle, E2,
and E2 + puerarin. The cells with brown color represent protein positive. E2-treated xenografts show a stronger signal for MMP-9, ICAM-1, and
VEGF, and a weaker signal for TIMP-1. Co-treatment with puerarin significantly suppressed this effect. 2: very weak staining; +: weak staining; ++:
strong staining; +++: very strong staining. n=6. NC: Negative control, Immunostaining for untreated group slice (omitting primary antibody).
doi:10.1371/journal.pone.0025011.g004
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hormonal treatments before the operation. All the samples were
obtained in the proliferative phase of the cycle, which was
confirmed histologically. This study was approved by the human
investigation committee of the Changhai Hospital, and written
informed consent was obtained from all patients.
The tissues were collected under sterile conditions and
transported to the laboratory on ice in Dulbecco’s modified
Eagle’s medium (DMEM) (PAA, Linz, Austria). The ESCs were
isolated as described by Kaei Nasul [8] and cultured in flasks with
DMEM containing 10% charcoal stripped fetal bovine serum
(FBS) (Biological Industries, Israel), 100 IU/mL penicillin, and
100 IU/mL streptomycin, which were then incubated in 5% CO2
at 37uC. For CAM experiments, tissue specimens were minced to
fragments of 262 mm using a scalpel in a sterile petri dish. Tissue
fragments that appeared to be necrotic were discarded.
The purity of ESCs in isolated cells cultured on a cover slip was
determined by fluoroimmunoassay of vimentin (mouse anti-
vimentin-PE monoclonal antibody, Thermo, Germany) as previ-
ously described [35]. Isotype mouse IgG1 PE (eBiosicence, USA)
was used as the control. The purity was calculated by vimentin-
stained cells in comparison with DAPI-stained cells.
Invasion assays
ESCs invasion was assayed in transwell chambers (Costar, USA)
according to the manufacturer’s instruction. Briefly, transwell
chambers with 6.5 mm polycarbonate filters of 8-mm pore size
were used. ESCs were starved overnight in serum-free medium
containing 0.1% BSA prior to initiation of the invasion assay. The
upper surface of the filter was coated with 20 ml 10 mg/ml
Matrigel (Beckon Dickinson Labware, USA). The number of cells
was adjusted to 5610
5/ml in DMEM containing 0.1% charcoal
stripped BSA, and 5610
4 cells was added to the top well after
Matrigel was polymerized. 600 ml DMEM containing 10%
charcoal stripped FBS was added to the bottom well. Cells were
treated with 1610
28 mol/L E2 (Sigma, NY, USA) or a
combination with 1610
29 mol/L puerarin (Sigma, NY, USA) or
normal saline containing 0.1% DMSO (v/v) for 12 h, the non-
invaded cells were completely wiped out with a cotton swab, and
the lower surface of the filter was fixed in methanol, stained with
HE, and counted under a microscope at a magnification of 2006
with a Leica Qwin system (Leica, Germany). For each test, the
cells in 5 randomly selected fields were determined, and the counts
were averaged. The results were from 6 independent experiments
(n=6).
Western blot analysis
To clarify whether puerarin could affect the levels of MMP-9
and TIMP-1 protein, ESCs were treated with above treatments at
37uC for 48 h. After the treatment procedures, cells were washed
by pre-cooled PBS and lysed RIPA buffer (50 mmol/L Tris–Cl
pH 7.4, 150 mmol/L NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium
deoxycholate) supplemented with 1 mmol/L PMSF. Protein
concentration was determined using the BCA
TM protein assay
kit (Pierce, IL). 30 mg protein samples were resolved by SDS-
PAGE and transferred to a polyvinylidene difluoride membrane
(Millipore, MA). MMP-9 and TIMP-1 protein were detected by
immunoblot with anti-MMP-9 and anti- TIMP-1 polyclonal
antibody (Santa Cruz, CA) at a 1:500 dilution or b-actin
(1:5000; Sigma, USA), then followed by incubation with
peroxidase-coupled secondary antibodies. A Supersignal kit
(Pierce, IL) was used to visualize the bands according to the
manufacturer’s instructions. Six independent experiments were
assessed (n=6).
Chick Chorioallantoic Membrane (CAM) Assay
The in vivo puerarin anti-estrogenic effect on angiogenesis of
ectopic lesions was evaluated using the CAM vessel development
assay with modifications as previously described [36]. Fertilized
chicken eggs were incubated in a standard egg incubator at 37uC
and 60%–70% relative humidity for 6 days. A circular window
1.5–2 cm in diameter was opened aseptically on the eggshell, and
minced tissue fragment was grafted into CAM. The window was
sealed with Para film and the eggs were replaced to the incubator.
After 24 h, the eggs were randomly assigned into three groups and
treated with a gelatin sponge (46464 mm) which was saturated
with 10
28 mol/L E2 or combination with 10
29 mol/L puerarin
or normal saline containing 0.1% DMSO (v/v). After 72 h the
area around the loaded gelatin sponge was photographed using a
Canon digital camera. The angiogenic index was defined as the
mean number of visible blood vessel branch points within the
defined area of the gelatin sponge. Assays for each test sample
were carried out using 6 eggs.
Immunohistochemistry assay
For immunohistochemistry, 5 mm paraffin sections of CAM
xenograft tissues were prepared and pretreated at 65uC for
2 hours, followed by deparaffinization. Antigen retrieval was
carried out before application of the primary antibodies (MMP-9,
TIMP-1, ICAM-1, and VEGF; 1:1000 dilution; Santa Cruz, CA,
USA) overnight at 4uC. Thereafter, the slides were incubated for
2 hours at room temperature with the secondary antibodies
conjugated with horseradish peroxidase (HRP; 1:100; DAKO,
Japan). HRP activity was detected using the Liquid DAB+Sub-
strate Chromogen System (DAKO, Japan). Finally, the sections
were counterstained with hematoxylin and photographed.
Data and Statistical Analysis
Data were represented as mean 6 SD. Statistical comparisons
between groups performed using 1-way ANOVA followed by
Student’s t-test. P,0.05 was considered statistically significant.
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